Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease
Status
Conditions
Treatments
Details and patient eligibility
About
Atherosclerotic coronary heart disease is a condition thought to involve low-grade inflammation. Several reports, clinical and epidemiological, have demonstrated that intake of fish oil may be beneficial in attenuating the inflammatory process. Still, however, there are lacking data in respect to whether differences in composition of various marine oils may influence the inflammatory status differently.
The hypothesis of the current study is that extract from the antarctic krill (Euphausia superba) is better than traditional fish oils when compared head-to-head with balanced composition of omega 3 content on inflammatory status.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age: 18-80 years
- Sex: Male and female
- Stable atherosclerotic coronary heart disease (heart attack >3 months ago or objectified angina pectoris).
- No hospitalization for heart disease last 3 months.
Exclusion criteria
- Unstable heart disease.
- Heart failure NYHA class III and IV.
- Previous valve and/or aortic surgery
- Significant concomitant disease (i.e. diseases with known inflammatory activation - e.g. various autoimmune diseases, chronic infections, significant acute infections three weeks before or during the study, connective tissue disease, arthritis, chronic pulmonary disease or serious liver- or kidney-disease).
- Simultaneous involvement in other clinical studies involving intervention.
- Planned operation or other invasive procedures (e.g. PCI etc.) during the study period.
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Leif Erik Vinge, MD, PhD; Lars Gullestad, Professor, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal